140results about "Cis-trans-isomerases" patented technology

Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and / or Skp.

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of the FK 506-binding protein 7, or prolylisomerase, as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

The instant invention pertains to the discovery of two novel regulatory mechanisms of NF-kB. The instant invention demonstrates that NF-kB is regulated by Pin1-catalyzed prolyl isomerization and ubiquitin-mediated proteolysis of p65. Accordingly, the instant invention provides methods for regulating NF-kB, and diseases and disorders associated with NF-kB. Further, the invention provides compositions capable of modulating the activity or expression of NF-kB, Pin1, and / or the proteolysis of p65.

The invention relates to a modified PIN4 gene, the wild type of which is as identified in SEQ ID No. 1, encoding the protein of SEQ ID No. 5, or the wild type of which encodes a protein that has a sequence similarity of at least 80% to SEQ ID No. 5, which modified PIN4 gene encodes a protein that comprises an amino acid change as a result of the modification, and which modified protein is capable of inducing parthenocarpic fruit set when present in a plant. The invention also relates to plants and fruits that carry the gene. Such plants are capable of parthenocarpic fruit set and the fruits do not contain seeds. The invention further relates to use of the gene in breeding and producing plants capable of parthenocarpic fruit set.

The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.

The presently-disclosed subject matter includes nanoparticles that comprise a plurality of assembled polymers. In some embodiments the polymers comprise a first block that includes hydrophilic monomers, the first block substantially forming an outer shell of the nanoparticle, and a second block that includes cationic monomers and hydrophobic monomers, the second block substantially forming a core of the nanoparticle. In some embodiments a polynucleotide is provided that is bound to the cationic monomers of the nanoparticle. The presently-disclosed subject matter also comprises methods for using the present nanoparticles to include RNAi in a cell as well as methods for making the present nanoparticles.

The present invention provides, for example, a set of two polypeptides exhibiting the nuclease activity with dependence on light or in the presence of a drug, in which an N-terminal side fragment and a C-terminal side fragment of a Cas9 protein are bound to each of two polypeptides which form a dimer with dependence on light or in the presence of a drug.

Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and / or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.

A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA fragmentation when depleted. Methods of identifying other Pin proteins and Pin-interacting proteins and identifying compositions which affect Pin activity or expression are also provided.

Disclosed herein plant propagation materials, methods of manufacturing, formulations and uses thereof. The plant propagation materials disclosed herein may comprise a strigolactone obtained by a biosynthetic process. The plant propagation material may comprise a chemical mimic of a strigolactone. The strigolactone may be 5-deoxystrigol. Methods of manufacturing the plant propagation materials may comprise a chemical process. Alternatively, methods of manufacturing the plant propagation material may comprise a biosynthetic process. The methods may comprise use of one or more polynucleotides. The polynucleotides may encode a metabolite. The polynucleotides may comprise one or more genes encoding one or more components of a strigolactone pathway.

This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatoryresponses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and / or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.

The present invention relates to a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an extracellular antigen-binding domain, a transmembrane domain and a intracellular first chemical inducer of dimerization binding domain 1 (CBD1); and (ii) an intracellular signalling component comprising a signalling domain and a second chemical inducer of dimerization binding domain 2 (CBD2); wherein CBD1 and CBD2 are capable of simultaneously binding to a chemical inducer of dimerization (CID); wherein, in the absence of the CID, binding of the antigen-binding component to antigen does not result in signalling through the signalling component; whilst, in the presence of the CID, the receptor component and the signalling component heterodimerize and binding of the antigen-binding domain to antigen results in signalling through the signalling domain.

A W303a Saccharomyces cerevisiae yeast cell which contains a polynucleotide that encodes a functional Bax polypeptide under the control of a galactose- inducible promoter that is integrated at the LEU2 chromosomal locus. A kit of parts comprising the yeast cells and a yeast plasmid vector suitable for transforming a cDNA library into the yeast cells. Use of the yeast cell for screening a cDNA library for a polynucleotide that is or encodes an inhibitor of B ax-mediated apoptosis. Genes and polypeptides that inhibit Bax-mediated apoptosis and which were identified from a human hippocampus cDNA library screened in the yeast cells. A method of combating Bax-mediated apoptosis in a cell using an inhibitor of Bax-mediated apoptosis which was identified from a human hippocampus cDNA library screened in the yeast cells. A method of promoting Bax-mediated apoptosis in a cell using an inhibitor or antagonist of the anti-apoptotic polypeptides identified from a human hippocampus cDNA library screened in the yeast cells.

The invention relates to engineered Escherichia coli capable of high-yield production of fumaric acid; specifically, fumarase coded genes fumA and fumC of Escherichia coli are knocked off, and maleic cis-trans isomerase gene from Serratia marcescens is converted to obtain the engineered Escherichia coli. The invention also discloses a method of synthesis of catalyzing fumaric acid from maleic acid by using the engineered Escherichia coli. The method includes culturing the engineered Escherichia coli by fermenting, subjecting the engineered Escherichia coli to high-density inductive expression when OD600 reaches 40-80, and applying the obtained fermentation broth to biochemical catalysis of maleic acid in presence of Engineered Escherichia coli to obtain fumaric acid. The genes fumA and fumC in the Escherichia coli are knocked off by using Red homologous recombination, a metabolic pathway of its fumaric acid to L-malic acid is cut off, the maleic cis-trans isomerase from Serratia marcescens is then expressed, and the obtained genetically-engineered Escherichia coli can efficiently convert maleic matrix to synthesize high-purity fumaric acid, there is nearly no L-malic acid byproduct synthesized, and basis is provided for the industrialized production of fumaric acid by whole-cell process catalysis of maleic acid.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for HAO1.

The present invention provides biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.

A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA fragmentation when depleted. Methods of identifying other Pin proteins and Pin-interacting proteins and identifying compositions which affect Pin activity or expression are also provided.

The invention discloses thermostability transformation of maleic acid cis-trans isomerase and application thereof, and belongs to the field of enzyme engineering. The maleic acid cis-trans isomerase gene maiA from serratia marcescens is subjected to thermostability transformation by a semi-rational design method. Compared with the wild maleic acid cis-trans isomerase, the obtained mutant has the advantages that the half-life period of the mutant G27A-G171A at 55 DEG C is 2.9 times of that of the wild type, and the enzyme activity is 1.96 times of that of the wild type; the half-life period of the mutant G27A-K104R is 4.18 times of the wild type at 55 DEG C, and the enzyme activity is 1.59 times of that of the wild type.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for HAO1.

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.

Propionibacterium acnes linoleate isomerase and its application. An amino acid sequence is as shown in SEQ ID NO.1. Through concerted catalysis of compound enzyme, conjugated linoleic acid can be directly prepared from plant oil containing high content of linoleic acid, thus overcoming the defect that conjugated linoleic acid must be produced by using expensive free linoleic acid as a substrate and saving costs greatly. Compound enzyme is prepared by the utilization of recombinant bacteria, thus raising enzyme activity and increasing enzyme output. There is no need to purchase commercial enzyme, and cost is saved effectively. The isomerization product conjugated linoleic acid contains single component and has a plurality of physiological activities. The scheme has good practicality. Good economic benefit can be produced. The propionibacterium acnes linoleate isomerase has a good industrial prospect.

The invention relates to a protein mutant, particularly a maleate cis-trans isomerase, and a coding gene and application thereof. The amino acid sequence of the maleate cis-trans isomerase is disclosed as SEQ ID NO.4, or an amino acid sequence with equal functions, which is derived from SEQ ID NO.4 and subjected to substitution, deletion or addition of one or more amino acids. Compared with the wild type maleate cis-trans isomerase, the changes of the specific amino acid sequence of the mutant as follows: K51I (the 51st lysine is changed into isoleucine), R177S (the 177th arginine is changed into serine), and A212G (the 212th alanine is changed into glycine). The test verifies that the enzyme activity of the mutant is enhanced by 2.71 times as compared with the wild type maleate cis-trans isomerase.